Skip to content
Home/Companies/Biotech/Emergence Therapeutics
ET

Emergence Therapeutics

Biotech·Germany·Exited 2023·Held 4yr

Emergence Therapeutics is a biotech company, headquartered in Germany.

Entry
2019
Hold
4yr
Exit
2023
Est. EV
–

Who owns Emergence Therapeutics?

Emergence Therapeutics was owned by Gruenderfonds Ruhr through Gruenderfonds Ruhr I (2017 vintage) from 2019 to 2023, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-07-03

Gruenderfonds Ruhr
Investor
Gruenderfonds Ruhr
Gruenderfonds Ruhr I · 2017 · VC

Key facts

HQGermany
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2023

More from Gruenderfonds Ruhr I

Other portfolio companies in the same fund.

LIDROTEC
Active
IndustrialsGermany· 2022
Spherity
Active
CybersecurityGermany· 2022
VMRay
Active
CybersecurityGermany· 2022
Advosense
Active
MedTechGermany· 2020
Masterplan
Exited 2025
SoftwareGermany· 2020
to
Abalos Therapeutics
Active
BiotechGermany· 2019

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings